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Raynaud’s phenomenon of the tongue after radiation therapy with or without chemotherapy is an exceedingly rare complication.
Symptoms are similar to Raynaud’s disease of other sites and involve pallor and discomfort on exposure to cold temperatures that
resolve with rewarming. Presentation occurs approximately 18-24 months after radiotherapy on average and can usually be
managed eﬀectively with lifestyle modiﬁcation and pharmacotherapy. Here, we present a case of lingual Raynaud’s following
surgery and adjuvant radiation therapy in a patient with squamous cell carcinoma of the oral cavity.

1. Introduction
Raynaud’s phenomenon (RP) is a vasospastic process that
typically aﬀects the digits of the hands, causing painful discoloration on exposure to cold temperatures or strong emotions [1]. It is estimated that 3-5% of the general population
is aﬀected by RP with a predilection for females and those in
more northerly regions [1]. Classically, it presents in three
phases beginning with pallor, which represents the initial
vasoconstrictive ischemic phase. After a prolonged period
of ischemia, the second phase of a cyanotic blue color results
from the presence of desaturated blood in the aﬀected part.
With recovery, there is a ﬁnal hyperemic phase of vasodilation which produces a red color. This classic color progression from white to blue to red is only infrequently present.
Episodes of vasospasm usually last from minutes to one hour
but can last multiple hours [1].
The precise mechanism for RP has not yet been
elucidated but current thinking points to a combination of
probable neural and vascular factors. The neural pathway
involves sympathetic nervous system stimulation by cold
temperatures or stress. The resulting release of norepineph-

rine activates vascular smooth muscle alpha adrenoreceptors
leading to vasoconstriction. However, local factors can override this neural response as seen in patients with local anesthesia of sympathetic nerves or postsympathectomy who can
still experience episodes of RP [1]. Another postulated
mechanism for RP is production of reactive oxygen species
(ROS) by mitochondria in response to cold temperatures
[1]. Signaling through the Rho/Rho-kinase pathway leads
to translocation and subsequent activation of α2C-adrenoreceptors causing vasoconstriction [1].
Small artery occlusive disease (e.g., vasculitis) is more
commonly implicated in secondary RP, which is associated
with collagen vascular diseases such as systemic sclerosis
[1]. Some of the vascular causes include endothelial cell
damage, disparate vasoactive substance production, intravascular narrowing, and increasing vasoconstriction [1].
Once exposed to cold, these factors increase the body’s natural vasoconstrictive response leading to the classical pale
skin of aﬀected areas [1, 2].
Development of management strategies has been hampered by the complex etiology of RP and a poor understanding of its exact mechanisms. Many therapies have been tried
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with varying degrees of success. They are broadly divided
into nonpharmacologic and pharmacological interventions.
Treatment is stratiﬁed based on severity, beginning with
nonpharmacological approaches for mild symptoms. These
include lifestyle modiﬁcation to avoid triggers such as keeping the aﬀected areas warm with clothing and avoiding
exposure to cold temperatures [1]. Smoking cessation is
always advised, if applicable [1]. For more severe symptoms,
vasodilator therapy is added, typically beginning with
dihydropyridine calcium channel blockers—nifedipine being
the most studied and drug of choice [1]. Other potential agents
include alpha-1 adrenoreceptor antagonists (prazosin),
angiotensin-converting enzyme inhibitors, nitric oxide, prostaglandin analogs, phosphodiesterase inhibitors, selective
serotonin reuptake inhibitors, antioxidants, botulinum toxin
A, endothelin receptor antagonists, and Rho inhibitors [1].
Alternative approaches include herbal remedies such as
Ginkgo biloba extract and rosemary oil, acupuncture, transcutaneous nerve stimulation, and sympathectomy among
others [1].
Although the primary regions aﬀected by RP are the
digits of the hands and feet, rarely aﬀected regions include
the nose, ears, lips, and nipples. Raynaud’s of the tongue is
exceedingly rare and to date is only described in a handful
of case reports.

2. Case
A 63-year-old postmenopausal female with a history of
hypertension, hyperlipidemia, and former 25 pack-year
tobacco use presented with squamous cell carcinoma of the
oral cavity pathological stage IVA (pT1N2bM0). She had
undergone wide local excision of an alveolar ridge lesion
with, left neck dissection of levels I-IV, and reconstruction
with a right radial forearm free ﬂap; the margins were negative, and there was no extranodal extension. She subsequently completed postoperative radiation therapy to a
dose of 60 Gy in 30 fractions using intensity-modulated radiation therapy (IMRT) to the areas shown in Figures 1(a) and
1(b). At follow-up, 19 months after radiation, she continued
to suﬀer from xerostomia and diminished taste sensation but
showed no evidence of disease based on clinical and radiologic examination. Approximately two years after completion of radiation, in the month of October, she began to
notice intermittent lingual pallor. She reported that the tip
and anterior 1/4 of her tongue predominately on the left side
began to tingle and turn white, lasting 10-15 minutes and
occurring two to three times per day as shown in Figure 2.
This change occurred mostly with exposure to cold ambient
temperatures and resolved with rewarming. Interestingly, it
did not occur with drinking cold beverages. There were no
motor, sensory, balance, or hearing changes or similar symptoms in the digits of the hands or feet. She had no history of
Raynaud’s disease, cerebrovascular accident, transient
ischemic attack, or other neurologic disease. Physical examination revealed no visible abnormality of the tongue and
ﬂexible laryngoscopy was unremarkable. A computed
tomography angiogram of the head and neck done to investigate possible vascular causes showed no signiﬁcant extra-
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cranial arterial occlusive disease or aneurysm. She was
referred to vascular surgery for further evaluation, and laboratory studies were ordered, showing an ESR 4 mm/Hr, CRP
0.2 mg/dL, PT 12.9 sec, PTT 25 sec, INR 0.97, DRVVT
35 sec, and lupus anticoagulant negative. Her presentation
was noted to be most consistent with Raynaud’s phenomenon of the tongue, and a trial of nifedipine extended release
30 mg daily was started. During follow-up several weeks
later, she reported signiﬁcant improvement in the frequency
and severity of symptoms and was tolerating treatment,
though attacks continued to occur intermittently when outdoors in cold temperatures.

3. Discussion
Raynaud’s phenomenon of the tongue is exceedingly
uncommon and often occurs in the setting of primary Raynaud’s disease of the digits. There have been at least 22 cases
of lingual involvement reported in the literature, usually
associated with systemic sclerosis, Sjögren’s syndrome, or
other connective tissue disorders [3–8]. Of the lingual Raynaud’s cases found in the literature, four were identiﬁed
without preexisting connective tissue disease all occurring
after the use of radiotherapy for head and neck squamous
cell carcinomas [2, 9–11]. In three cases, there was no history of Raynaud’s disease aﬀecting the digits and in all cases,
radiotherapy had occurred between 18 and 54 months prior
to the onset of symptoms. One of the patients was noted to
have a smoking history while the other three were either
nonsmokers or not speciﬁed. Nicotine is noted to be a risk
factor for Raynaud’s disease and was potentially a contributing factor in our patient [1].
Interestingly, 2/4 cases involved male patients, while typical RP tends to aﬀect females more than males. One risk
factor for RP is the hormone estrogen, which potentiates
vasoconstriction occurring via alpha adrenoreceptors [1].
Further evidence for this factor comes from estrogen therapy
increasing the risk of RP in postmenopausal women [1]. Our
patient was not on estrogen therapy. Raynaud’s phenomenon can result from either increased vasoconstriction or
impaired vasodilation or a combination of the two in small
arteries. Underlying arterial occlusive disease can be a major
contributing factor. Arteries narrowed by such a process
have a lower “critical closing pressure,” and normal coldinduced vasoconstriction can lead to temporary vessel closure. Radiation leads to a progressive obliterative endarteritis
of small vessels which makes them prone to such changes
and may be a contributing factor to the rare occurrence of
RP [2]. Additionally, radiation damage to the endothelium
disrupts normal chemical mediators of vasorelaxation. The
result is exaggerated vasoconstriction, both in intensity and
duration, to normal adrenergic-mediated stimuli (e.g., cold
or stress) and impaired vasodilation leading to the classic
symptoms of RP [2]. Surgery is also likely a contributing factor from scarring leading to compression of small arterial
beds [11].
Non-RT-associated cases in this group of lingual Raynaud’s
patients tended to occur in younger people and females, often
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Figure 1: (a, b) Dose lines of radiotherapy treatment showing irradiated regions of the oral cavity.

ations until further data in this speciﬁc patient population
become available.

4. Conclusion
In summary, lingual Raynaud’s phenomenon is a rare complication of radiation therapy to the oral cavity. Although
the exact mechanism is currently unknown, the etiology is
likely related to radiation-induced small artery damage
resulting in an exaggerated vasoconstrictive response to normal adrenergic stimulation. Treatments can be eﬀective in
mitigating symptoms and include lifestyle changes and
pharmacologic intervention.
Figure 2: Picture of the oral tongue demonstrating left-sided
tongue pallor.

with a previously diagnosed systemic sclerosis with digital
Raynaud’s symptoms [3–8].
Treatment of our patient using calcium channel blockers
was apparently eﬀective, though other options ranging from
lifestyle changes of avoiding colder temperatures up to
recurrent botulinum toxin injections seemed acceptable [2,
9–11]. Three of the other cases demonstrated stable disease
with nonpharmacologic management, leading to ongoing
intermittent pain attacks that were reported as self-limiting
and tolerable [2, 9, 10]. One patient was treated with ﬁfty
units of botulinum toxin injected along the sternocleidomastoid muscle, which provided complete resolution of the
patient’s discoloration, paresthesia, and dysphagia for 3
months until symptoms gradually returned [11]. Repeat
injections reportedly had similar eﬀect to the ﬁrst [11].
Overall, the treatment paradigm for lingual Raynaud’s after
RT seems to mirror the general consensus for primary
Raynaud’s disease. Severity of symptoms and patient
preference for intervention should be the main consider-
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